Advancing Alternative Bioequivalence for OINDPs
Nanopharm & Fluidda explore FDA’s progress in alternative bioequivalence for OINDPs, Model Master Files (MMF), and future regulatory pathways.
In Silico Bioequivalence Beyond Generic Drug Development
Nanopharm & Fluidda discuss FDA’s in silico bioequivalence methods for alternative pathways beyond generics in inhalation drug development.
FDA’s Evolving Stance on In-Silico Studies in Bioequivalence Testing
Discover how the FDA’s evolving view on in-silico methods, with insights from Nanopharm and FLUIDDA, impacts bioequivalence and generic drugs.
Nanopharm Newsletter November 2024
Nanopharm is leading innovation in OINDP, inhalation, and nasal drug delivery with FDA collaboration and advanced spray-drying technology.
FDA New Inhaled Product Guidelines: Bioequivalence & PSGs
Explore Nanopharm & Fluidda discuss FDA’s revised inhaled product guidelines (PSGs) and alternative bioequivalence pathways for generics.
Interview with Jane Provis Evans, Head cGMP services at Nanopharm
In the ever-evolving world of pharmaceuticals, the importance of stringent quality control cannot be overstated. This interview with Jane Provis-Evans, Head of cGMP Analysis at Nanopharm, sheds light on the critical role of cGMP testing in the development and optimization of drug-device combinations, particularly for orally inhaled and nasal drug products (OINDPs). With the launch of Nanopharm’s new GMP services, the company is well-positioned to help clients bring innovative treatments to patients.
Dry Powder Inhaler Formulations: Microstructural Analysis Techniques
The paper titled “Microstructural Characterization of Dry Powder Inhaler Formulations Using Orthogonal Analytical Techniques” explores the use of advanced analytical methods to improve our understanding of the performance of dry powder inhalers (DPIs).
Exploring PBPK Modeling in Nasal Drug Delivery: Expert Insights from Will Ganley
Explore PBPK modeling for OINDP and nasal drug delivery, optimizing drug development and reducing clinical trial needs
Nanopharm & Fluidda Discuss FDA’s New Inhaled Product Guidelines
Explore how alternative bioequivalence methods, including computational fluid dynamics and in silico modeling, are shaping the future of generic drug approval.
Interview with Rob Bootle: Advancements in Nanopharm’s OINDPs
Join Rob Bootle as he explores his journey at Nanopharm, highlighting the company’s cutting-edge research and development in orally inhaled and nasal drug products (OINDPs).
